Zobrazeno 41 - 50
of 192
pro vyhledávání: '"Ryuji Yasumatsu"'
Autor:
Tae, Gondo, Kimie, Fujita, Mika, Nagafuchi, Tsukasa, Obuchi, Daisaku, Ikeda, Ryuji, Yasumatsu, Takashi, Nakagawa
Publikováno v:
Auris Nasus Larynx. 47:643-649
This study aimed to investigate the incidence of postoperative pneumonia (PP) and surgical site infection (SSI) in head and neck cancer (HNC) patients and clarify the relationship between oral care and postoperative infection.We conducted a retrospec
Autor:
Ryuji Yasumatsu, Takahiro Hongo, Ryutaro Uchi, Masahiko Taura, Rina Jiromaru, Takashi Nakagawa, Mioko Matsuo, Takahiro Wakasaki
Publikováno v:
Acta Oto-Laryngologica. 140:698-703
Background: Sinonasal squamous cell carcinoma (SCC) is a rare tumor arising either de novo or in association with inverted papillomas (IPs).Objectives: The aim of this study was to investigate and compare the oncological features and prognosis of pat
Autor:
Junichi Fukushima, Hideki Kadota, Satoshi Toh, Ryuji Yasumatsu, Sei Yoshida, Kenichi Kamizono, Muneyuki Masuda, Takashi Nakagawa, Torahiko Nakashima
Publikováno v:
Journal of Plastic, Reconstructive & Aesthetic Surgery. 73:740-748
Summary Background As the base of the tongue (BOT) plays essential roles in speech and swallowing, surgical resection of BOT cancer is typically avoided. Moreover, standard reconstructive procedures for larynx-preserving BOT defects have not yet been
Publikováno v:
Toukeibu Gan. 46:385-389
Autor:
Ryuji Yasumatsu, Ryutaro Uchi, Masahiko Taura, Takahiro Wakasaki, Takashi Nakagawa, Mioko Matsuo
Publikováno v:
JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY. 29:273-278
Autor:
Ryutaro Uchi, Ryuji Yasumatsu, Masahiko Taura, Takahiro Wakasaki, Takashi Nakagawa, Mioko Matsuo
Publikováno v:
Toukeibu Gan. 46:41-45
Autor:
Kazuo Nishiyama, Teppei Noda, Ryuji Yasumatsu, Masanobu Sato, Koichiro Nakashima, Akihiro Tamae, Hidetaka Yamamoto
Publikováno v:
Toukeibu Gan. 46:59-63
Publikováno v:
Practica Oto-Rhino-Laryngologica. 113:309-314
Autor:
Yoshihiro Matsumoto, Hitoshi Kusaba, Hiroshi Ariyama, Ryuji Yasumatsu, Eishi Baba, Junji Kishimoto, Makoto Endo, Shohei Moriyama, Toshifumi Fujiwara, Nokitaka Setsu, Koichi Akashi, Takahiro Wakasaki, Kenji Tsuchihashi, Kenta Nio, Yasuharu Nakashima, Mitsuhiro Fukata, Kyoko Yamaguchi, Mamoru Ito, Tomoyasu Yoshihiro, Keisuke Taguchi
Publikováno v:
International Journal of Surgery Oncology. 5:e891-e896
Tyrosine kinase inhibitors (TKI) work against various types of cancer by inhibiting angiogenic signaling. Little is understood about the incidence, characteristics, and risk factors associated with thromboembolism induced by TKI in routine clinical p
Autor:
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G M Hughes, Ricard Mesía, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey-Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gumuscu, Jonathan D Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan Jose Zarba, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Anne Taylor, Martin Burian, Carlos Henrique Barrios, Dalvaro Oliveira de Castro Junior, Gilberto Castro, Fabio Andre Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Santos, Ana-Paula Victorino, Neil Chua, Felix Couture, Richard Gregg, Aaron Hansen, John Hilton, Joy McCarthy, Denis Soulieres, Rodrigo Ascui, Pablo Gonzalez, Luis Villanueva, Marco Torregroza, Angela Zambrano, Petra Holeckova, Zdenek Kral, Bohuslav Melichar, Jana Prausova, Milan Vosmik, Maria Andersen, Niels Gyldenkerne, Hannes Jurgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Dora Kwong, Yousuf Al-Farhat, Tibor Csoszi, Jozsef Erfan, Geza Horvai, Laszlo Landherr, Eva Remenar, Agnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nole, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi, Nobuya Monden, Masahiro Nakayama, Kenji Okami, Nobuhiko Oridate, Kiyoto Shiga, Yasushi Shimizu, Masashi Sugasawa, Masanobu Takahashi, Shunji Takahashi, Kaoru Tanaka, Tsutomu Ueda, Hironori Yamaguchi, Tomoko Yamazaki, Ryuji Yasumatsu, Tomoya Yokota, Tomokazu Yoshizaki, Iveta Kudaba, Zinaida Stara, Soon Keat Cheah, Jose Aguilar Ponce, Rene Gonzalez Mendoza, Carlos Hernandez Hernandez, Francisco Medina Soto, Jan Buter, Ann Hoeben, S. Oosting, Karijn Suijkerbuijk, Aase Bratland, Marianne Brydoey, Renzo Alvarez, Luis Mas, Priscilla Caguioa, John Querol, Eugenio Emmanuel Regala, Maria Belen Tamayo, Ellie May Villegas, Andrzej Kawecki, Andrey Karpenko, Arkadiy Klochikhin, Alexey Smolin, Oleg Zarubenkov, Boon Cher Goh, Graham Cohen, Johanna du Toit, Christa Jordaan, Gregory Landers, Paul Ruff, Waldemar Szpak, Neonyana Tabane, Irene Brana, Lara Iglesias Docampo, Javier Lavernia, Ricard Mesia, Edvard Abel, Valentina Muratidu, Niels Nielsen, Valerie Cristina, Sacha Rothschild, Hung-Ming Wang, Muh-Hwa Yang, Su-Peng Yeh, Chia-Jui Yen, Nopadol Soparattanapaisarn, Virote Sriuranpong, Sercan Aksoy, Irfan Cicin, Meltem Ekenel, Hakan Harputluoglu, Ozgur Ozyilkan, Kevin Harrington, Sanjiv Agarwala, Haythem Ali, Robert Alter, Daniel Anderson, Justine Bruce, Nicholas Campbell, Miguel Conde, John Deeken, William Edenfield, Lawrence Feldman, Elizabeth Gaughan, Basem Goueli, Balazs Halmos, Upendra Hegde, Brian Hunis, Robert Jotte, Anand Karnad, Saad Khan, Noel Laudi, Douglas Laux, Danko Martincic, Steven McCune, Dean McGaughey, Krzysztof Misiukiewicz, Deborah Mulford, Eric Nadler, Johannes Nunnink, James Ohr, Meaghan O'Malley, Brian Patson, Doru Paul, Elizabeta Popa, Steven Powell, Rebecca Redman, Vincent Rella, Chaio Rocha Lima, Abirami Sivapiragasam, Yungpo Su, Ammar Sukari, Stuart Wong, Emrullah Yilmaz, Jeffrey Yorio
Publikováno v:
The Lancet, 394(10212), 1915-1928. ELSEVIER SCIENCE INC
BACKGROUND: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.METHODS: KEYNOTE-048 was a randomised, phase 3 study of participants with u